• Active Substance: Midostaurin
  • Name: Rydapt®
  • Therapeutic area: Acute myeloid leukaemia (AML)
  • Pharmaceutical company: Novartis Pharma GmbH


Time table:

  • Publication of project plan: 20.06.2017
  • Publication of final assessment: 08.11.2017


Assessment information:

  • Title: Midostaurin for the indication of Acute Myeloid Leukaemia
  • Author/Co-Author: FIMEA (Finnland), NOMA (Norway)
  • Dedicated Reviewers: TLV (Sweden), ZIN (Netherlands), HAS (France), AEMPS (Spain) 
  • Information retrieval: IQWIG (Germany)
  • Observer: SUKL (Czech Republic), EOPYY (Greece), SESCS (Spain)

› G-BA assessment available (D-319)